A Phase 3 Randomized Double-Blind Placebo-Controlled Stu

Project: Research project

Description

A Phase 3 randomized Double-blind Placebo-controlled study of ARQ 197 plus erlotinib versys polacebo plus erlotinib in previously treated subjects with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC)
StatusFinished
Effective start/end date11/1/106/1/13

Funding

  • DAIICHI SANKYO PHARM DEV

Fingerprint

Non-Small Cell Lung Carcinoma
Placebos
Erlotinib Hydrochloride
ARQ 197